Published:


Measuring Cognition and Function in the Preclinical Stage of Alzheimer's Disease

National Institute on Aging – Alzheimer’s Association Research Framework Lays the Groundwork for Deeper Understanding of Alzheimer’s disease

Neuropsychiatric Signs and Symptoms of Alzheimer's Disease: New Treatment Paradigms

Tau: From research to clinical development

The Roles of Inflammation and Immune Mechanisms in Alzheimer's Disease

Additional/Co-morbid Neuropathologies in the setting of Alzheimer’s Disease
Neuropathology: Impact on Drug Development

Challenges, Solutions and Consensus Recommendations for Alzheimer's Disease Combination Therapy

Considerations for the assessment of suicidal ideation and behavior in older adults with cognitive decline and dementia

Revolution of Alzheimer’s Disease Understanding and Trials Through Biomarkers

Assessing Cognition and Function in Alzheimer’s Disease Clinical Trials: Do We Have the Right Tools?

Justifying Reimbursement for Alzheimer’s Diagnostics and Treatments: Seeking Alignment on Evidence

Revisiting the Framework of the National Institute on Aging-Alzheimer’s Association Diagnostic Criteria, October 2012

Let’s Get Real About Non-Amyloid Targets in Alzheimer’s Disease, April 2012

Prevention Trials in Alzheimer’s Disease, October 2011

**Phase II Clinical Trials in Alzheimer's Disease, June 2011**

**Epidemiology of Alzheimer’s Disease, October 2010**

**VE Expert Working Group Meeting, October 2010**

**Challenges in NPS in Alzheimer’s Disease, April 2010**

**Global Clinical Trials in Alzheimer’s Drug Development Meeting, November 2009**

**Alzheimer’s Disease Classification Meeting, April 2009**

**Optimal Trial Design for Alzheimer’s Drug Discovery Meeting, November 2008**
Not published

**Scales for Alzheimer's Disease Meeting, April 2008**
Early Risk Assessment for Alzheimer’s Disease Meeting, November 2007

Academic/Industry Interface for Alzheimer’s Drug Discovery Meeting, April 2007

Health Economics & Real World Value of AD Therapy Meeting, November 2006:


Cytoskeletal Meeting, April 2006:


**Optimal Trial Design Meeting, November 2005:**


Finding potent drugs for Alzheimer’s disease is more important than proving the drugs are disease modifying. Knopman, D. *Alzheimer’s & Dementia* (2006).


**Biomarkers Meeting, April 2005:**

**MCI Meeting, September 2004:**